- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02796885
Characterisation of Adult-Onset Hypophosphatasia
Hypophosphatasia (HPP) is an inherited condition which causes a defect in bone calcification, leading to weak bones. Early childhood forms are severe and easily recognised, and there is now a drug treatment which is very effective in children.
Adult forms are milder, often missed by doctors or confused with osteoporosis. This is important because the usual osteoporosis treatments may be harmful in HPP, and increase the risk of broken bones. One of the reasons it is missed is a lack of research describing the typical features of HPP, so doctors don't recognise the signs, and don't know when or how to test for it.
The aim of this study is to establish clear criteria (from clinical history, examination and blood tests) to identify people with HPP. The results will also determine if there should be a trial of drug treatment for adults with HPP.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypophosphatasia (HPP) is a genetic disorder caused by mutation in the tissue-non-specific alkaline phosphatase gene (TNSALP). It causes impaired bone mineralisation, fractures, tooth loss, muscle weakness and possibly other adverse health outcomes.
The infantile-onset forms are severe, and were often fatal until the recent availability of a treatment (Asfotase Alfa, Alexion Pharma). The childhood-onset forms are less severe, and the adult-onset form is mild, and often unrecognised or misdiagnosed as osteoporosis.
The less severe forms of the disease are not well described, and because there has been no available treatment there has not been much research in adults. However, now that treatment is available there is a possibility of a clinical trial in adults.
Additionally, patients with hypophosphatasia are often not recognised, and are misdiagnosed as having osteoporosis. This is important because patients with hypophosphatasia are at risk of developing atypical femoral fractures if they are treated with usual osteoporosis medication (bisphosphonates).
A major contributor to the under-recognition of adult HPP is the lack of phenotypic description and biomarker definitions. The aim of this project is to identify the clinical and biochemical characteristics that identify HPP.
In preparation for this study reference ranges for the commonly used HPP biomarkers (ALP and PLP) have been established, and used to screen 2000 patients presenting to metabolic bone services in Sheffield and Oxford.
For this study, patients who have biochemistry suggestive of HPP (low ALP and high PLP), will undergo a detailed clinical assessment, with medical history, physical examination, bone biochemistry, targeted musculoskeletal imaging and HPP gene testing. Their results will be compared with a control group of metabolic bone clinic patients with normal ALP and PLP, and a group of patients with known gene-proven and clinically manifest HPP.
The results will establish clinical phenotype and biomarker criteria for HPP diagnosis, which could be incorporated into future pathways for patients presenting to metabolic bone clinics. This will improve the identification of HPP and prevent harm from incorrect treatment with bisphosphonates.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7HE
- Nuffield Orthopaedic Research
-
Sheffield, United Kingdom, S10 2TN
- University of Sheffield
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- As the groups described above
- Able and willing to participate in the study and provide written informed consent
Exclusion Criteria:
- Other conditions known to affect serum ALP and PLP (Coeliac disease, B12 deficiency, untreated hypothyroidism, Wilson's disease)
- Taking nutritional supplements containing vitamin B6
- Pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Possible hypophosphatasia
Patients attending metabolic bone services, not previously know to have HPP, with biochemistry suggestive of HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
|
|
Normal
Patients attending metabolic bone services, not previously know to have HPP, with normal HPP biochemistry Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
|
|
Known hypophosphatasia
Patients attending metabolic bone services or registered with RUDY database, known to have HPP Will have TNSALP gene test, clinical assessment for possible features of HPP, bone turnover marker profile.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALP and PLP
Time Frame: baseline cross-sectional
|
predictive value of low ALP with high PLP for TNSALP mutation (ROC curve)
|
baseline cross-sectional
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALP:PINP ratio
Time Frame: baseline cross-sectional
|
predictive value of ALP:PINP ratio for TNSALP mutation (ROC curve)PP
|
baseline cross-sectional
|
prevalence of imaging-confirmed musculoskeletal pathology in patients with HPP
Time Frame: baseline cross-sectional
|
History and clinical examination will be obtained to identify possible musculoskeletal pathology. Imaging (x-ray, ultrasound or MRI) will be obtained to determine the nature of the pathology. Will include arthritis, enthesopathy, tendonitis. Prevalence of musculoskeletal pathology in people with biochemistry suggestive of HPP and positive gene test will be compared with normal controls. |
baseline cross-sectional
|
short physical function battery score
Time Frame: baseline cross-sectional
|
physical function battery score in people with biochemistry suggestive of HPP and positive gene test (compared with normal controls)
|
baseline cross-sectional
|
Collaborators and Investigators
Investigators
- Principal Investigator: Richard Eastell, University of Sheffield
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STH18683
- 16/NW/0385 (Other Identifier: UK HRA REC)
- 202179 (Other Identifier: UK HRA IRAS)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypophosphatasia
-
AlexionEnrolling by invitationHypophosphatasia (HPP)France, Poland, United Kingdom, Germany, Spain, Saudi Arabia, United States, Canada, Russian Federation, Australia, Italy
-
Hvidovre University HospitalOdense University HospitalActive, not recruitingHypophosphatasia (HPP)Denmark
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada, United Arab Emirates, United Kingdom
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Turkey, Australia, Germany, United Kingdom, Argentina, France, Canada, India
-
Alexion Pharmaceuticals, Inc.Not yet recruiting
Clinical Trials on no intervention - observational study
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
University Hospital, Basel, SwitzerlandCompletedPostoperative Complications | Intraoperative Complications | Patient Safety | Risk ManagementNew Zealand, Switzerland, United States, Netherlands, Spain, Austria, Turkey, United Kingdom, Australia, Greece, Ireland, Italy
-
Hôpital Necker-Enfants MaladesUnknown
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; Wellcome Trust; University of... and other collaboratorsRecruitingKidney Diseases | Chronic Kidney Diseases | Non-communicable Disease | Non-Communicable Chronic DiseasesMalawi
-
Nanfang Hospital of Southern Medical UniversityThe First Affiliated Hospital of Anhui Medical University; Xiangya Hospital... and other collaboratorsRecruiting
-
RenJi HospitalNot yet recruitingEnd Stage Renal Disease on DialysisChina
-
Nanowear Inc.RecruitingElective Surgical ProceduresUnited States
-
Manchester University NHS Foundation TrustUniversity of Oxford; University of LiverpoolCompletedPremature Birth | Enterocolitis, Necrotizing | Gastroschisis | Meconium Ileus | Bowel Obstruction | Atresia; Bowel | Perforation BowelUnited Kingdom